Amedisys — Q1 2023 Earnings Presentation
18 slides from Amedisys's earnings presentation, May 3, 2023
Slide 1: Amedisys First Quarter 2023 Earnings Release Supplemental Slides
1 Amedisys First Quarter 2023 Earnings Release Supplemental Slides May 3rd, 2023 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c
Slide 3: Our Key Areas of Focus
3 OUR KEY AREAS OF FOCUS Strategic areas of focus and progress made during Q1’23 • Home Health*: Total same store admissions +8% • Hospice: Total same store admissions -5%, ADC -1% • Personal Care: PC Network drove ~$262K in revenue to Home Health and Hospice via care coordination • High Acuity Care
Slide 4: Highlights and Summary Financial Results (Adjusted): 1Q23
4 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 1Q 2023(1) Home Health total same store admissions +8%; Hospice same store admissions -5%; EBITDA margin decline driven by the return of sequestration ($9M), planned wage increases and the shift in Home Health volumes from episodic to per visit
Slide 5: Revenue Mix and Reimbursement by Payor
5 62.7% 12.0% 25.3% Home Health Revenue Medicare FFS Private Episodic Per Visit 61.7% 34.8% 2.7% 0.8% Amedisys Consolidated Revenue Home Health Hospice Personal Care High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us f
Slide 6: Home Health and Hospice Segment (Adjusted) – Q1 2023
6 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q1 2023(1) • Revenue per Episode down 1.3% due to the reinstatement of sequestration at 2.0%. Reimbursement is flat year over year. • Y/Y Total CPV up $4.16 (+3.9%) primarily due to raises, an increase in salaried employees, higher contractor costs (COV
Slide 7: General & Administrative Expenses – Adjusted
7 $ in Millions 1Q22 2Q22 3Q22 4Q22 1Q23 Home Health Segment - Total 83.2 88.7 87.7 89.9 89.0 % of HH Revenue 24.8% 25.5% 25.9% 26.2% 25.9% Hospice Segment - Total 51.3 50.8 48.6 50.8 47.9 % of HSP Revenue 26.6% 25.6% 24.4% 25.7% 24.8% Personal Care Segment - Total 2.2 2.3 2.3 2.4 2.2 % of PC Revenu
Slide 8: Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted
8 OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED YOY Total CPV impacted by labor cost pressures and prior year benefit related to COVID contractor add-back. *Note: Direct comparison with industry competitors CPV calculation ** Note: In 1Q’22, the addback of COVID costs reduced Vis
Slide 9: Driving Top Line Growth
9 DRIVING TOP LINE GROWTH Home Health admissions growth remains strong; volume impacted by mix shift. Sequential Hospice average daily census decline due to softer admission volumes and seasonality. 0% -2% 1% 1% 5% 2% 0% 5% 5% 8% -4.0% -2.0% 0.0% 2.0% 4.0% 6.0% 8.0% 50,000 100,000 150,000 1Q22 2Q22
Slide 10: Industry Leading Quality Scores
10 3.00 3.50 4.00 4.50 PS Industry Performance Amedisys PS Score PS Industry Avg PS Top Competitor 3.00 3.50 4.00 4.50 QPC Industry Performance Amedisys QPC Industry Avg QPC Top Competitor INDUSTRY LEADING QUALITY SCORES Metric Oct 22 Release Jan 23 Release Apr 23 Preview Jul 23 Preview Quality of P
Slide 11: Hospice Quality: Moving Towards Best-in-Class
11 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. Exhibit 99.2
Slide 12: Debt and Liquidity Metrics
12 DEBT AND LIQUIDITY METRICS Net leverage ~1.3x 1. Net debt defined as total debt outstanding ($403.4M) less cash ($69.1M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($253.6M). 3. Liquidity defined as the sum of cash balance and available revolving
Slide 13: Cash Flow Statement Highlights
13 CASH FLOW STATEMENT HIGHLIGHTS (1) Total cash flow from operations for Q1-23 of $26M. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 1Q22 2Q22 3Q22 4Q22 1Q23 GAAP Net Income 31 .7 29.0 25.4 31 .5 24.9 Changes in
Slide 14: Income Statement Adjustments
14 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-G
Slide 15: 2023 Guidance
15 2023 Guidance Exhibit 99.2
Slide 16: Amedisys 2023 Updated Guidance
16 AMEDISYS 2023 UPDATED GUIDANCE Updated Revenue, EBITDA and EPS guidance ranges for FY 2023 ($M except for EPS) Original Guidance Updated Guidance Adjusted Revenue $2,244 - $2,274 $2,254 - $2,274 Adjusted EBITDA $230 - $240 $235 - $245 Adjusted EPS $4.13 - $4.36 $4.14 - $4.36 Exhibit 99.2
Slide 17: Environmental, Social, Governance (E.S.G.) Considerations
17 Environmental, Social, Governance (E.S.G.) Considerations Exhibit 99.2
Slide 18: Environmental, Social, Governance (E.S.G.) Considerations
18 ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS Sustainable, high-quality, patient focused, home-based care model Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental health has a strong correlation with physic